Incepto Medical

The firm addresses the growing pressure on healthcare professionals from increasing patient volumes and imaging data. Its business model is twofold, functioning as both a distributor of curated, third-party AI solutions and a co-creator of new applications. This dual approach involves partnering with medical centers to develop proprietary AI tools for specific clinical needs not yet met by the market, such as ARVA for aortic aneurysm diagnostics and KEROS for knee MRIs. Simultaneously, Incepto provides a subscription-based platform that offers seamless access to a portfolio of carefully selected AI applications from leading vendors. This platform integrates directly into existing hospital workflows and equipment, including PACS/RIS infrastructure, allowing for immediate use without new hardware investments.

The company's platform delivers a suite of applications for various imaging specialties like radiology, mammography, CT scanning, and nuclear medicine. By providing tools for detecting conditions such as cancer and assisting in emergency diagnostics, the platform helps to standardize diagnoses, reduce examination times, and enhance operational efficiency for its clients, which include hospitals, clinics, and radiology networks across Europe. Having raised a total of $33.3 million over several funding rounds, with a significant Series B of €27 million in 2022 led by LBO France, Incepto has expanded its reach. The company now serves over 100 clinical sites and processes more than 100,000 patient exams monthly, with a presence in multiple European countries and the United States.